Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-02
2007-10-02
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S125000, C546S112000, C514S299000
Reexamination Certificate
active
10548782
ABSTRACT:
Certain novel bicyclic N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
REFERENCES:
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6255319 (2001-07-01), Jegham et al.
patent: 2002/0115662 (2002-08-01), Boyd et al.
patent: 2005/0176772 (2005-08-01), Calabrese et al.
patent: WO 99/64002 (1999-12-01), None
patent: 0047571 (2000-08-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/70337 (2001-09-01), None
patent: WO 01/70708 (2001-09-01), None
patent: WO 01/91752 (2001-12-01), None
patent: WO 02/059095 (2002-08-01), None
patent: WO 02/059107 (2002-08-01), None
patent: WO 02/059108 (2002-08-01), None
patent: WO 02/059117 (2002-08-01), None
patent: WO 02/067869 (2002-09-01), None
patent: WO 02/068387 (2002-09-01), None
patent: WO 02/068388 (2002-09-01), None
patent: WO 03/007949 (2003-01-01), None
patent: WO 03/009847 (2003-02-01), None
patent: WO 03/106456 (2003-12-01), None
patent: WO 2005/009950 (2005-02-01), None
Steffen et al., Expert Opin. Emerging Drugs, “Emerging drugs for eating disorder treatment”, 2006, vol. 11, pp. 315-336.
Bays et al., obesity Research, “Currenht and investigational antiobesity agents and obesity therapeutic treatment targets”, 2004, vol. 12, pp. 1197-1211.
Wessells et al., J. of Urology, vol. 160(2), (1998), pp. 389-393, “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction . . . ”.
Giraudo et al., Brain Research, vol. 809 (1998), pp. 302-306, “Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands”.
Holder et al., J. Med. Chem., vol. 45 (2002), pp. 2801-2810, “Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 at the mouse melanocortin receptors . . . ”.
Kopelman, Nature, vol. 404 (2000), pp. 635-643, “Obesity as a medical problem”.
Wessells et al., Urology (2000), vol. 56, pp. 641-646, “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction”.
Dorr et al., Life Sciences, vol. 58 (1996), pp. 1777-1784, “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study”.
Moreland et al., Life Sciences, vol. 62 (1998), pp. 309-318, “Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells”.
Gingell et al., Exp. Opin. Ther. Patents (1999), vol. 9(12), pp. 1689-1696, “Emerging pharmcological therapies for erectile dysfunction”.
Dinsmore et al., BMJ, vol. 318 (1999), pp. 387-390, “ABC of sexual health: Erectile dysfunction”.
Chen et al., Cell, vol. 91 (1997), pp. 789-798, “Exocrine gland dysfunction in MC5-R-deficient mice: . . . ”.
Kask et al., Biochem. & Biophys. Res. Comm., vol. 245 (1998), pp. 90-93, “Selective antagonist for the melanocortin 4 receptor (HS014) increases food intake in free-feeding rats”.
Huszar et al., Cell, vol. 88 (1997), pp. 131-141, “Targeted disruption of the melanocortin-4 receptor results in obesity in mice”.
Hill et al., Science, vol. 280 (1998), pp. 1371-1374, “Environmental contributions to the obesity epidemic”.
Davidson et al., JAMA, vol. 281 (1999), pp. 235-242, “Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat”.
Guy Grand et al., Lancet, vol. 2 (1989), pp. 1142-1145, “Therapeutics: International trial of long-term dexfenfluramine in obesity ”.
Bray et al., Obesity Research, vol. 7 (1999), pp. 189-198, “Sibutramine produces dose-related weight loss”.
Douglas et al., Int. J. Obes. vol. 7 (1983), pp. 591-595, “Plasma phentermine levels, weight loss and side-effects”.
Yoram et al., Current Opinion in Urology, vol. 7 (1997), pp. 349-353, “Oral pharmacotherapy in erectile dysfunction”.
Peptides: Frontiers of Peptide Science, Fifteenth American Peptide Symposium, Jun. 14-19, 1997 (Nashville, TN).
Heaton et al., Int'l J. of Impotence Research, vol. 9 (1997), pp. 115-121, “A therapeutic taxonomy of treatments for erectile dysfunction: An evolutionary imperative”.
Graul, Drug News & Perspectives, vol. 9(9) (1996, pp. 572-575, “Latest findings on the diagnosis and treatment of erectile dysfunction”.
Corcos et al., Society for Neuroscience, vol. 23 (1997), Abstract 267.9, “HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats”.
Guo Liangqin
Nargund Ravi P.
Ye Zhixiong
Brown Baerbel R.
Fitch Catherine D.
Merck & Co. , Inc.
Rahmani Niloofar
Seaman Margaret D.
LandOfFree
Bicyclic piperidine derivatives as melanocortin-4 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic piperidine derivatives as melanocortin-4 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic piperidine derivatives as melanocortin-4 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3837703